Healthcare
Therma Bright Inc.(TBRIF)
Live Price
Offline$0.034
+0.00% today
1Y Change
-57.50%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +207.9%
- EPS Growth
- -616.7%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Therma Bright Inc. (TBRIF) is a Healthcare stock with listed on OTC. The stock last traded around $0.03 and down 57.5% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +207.9%, EPS growth of -616.7%, a dividend yield of 0.0%. What stands out right now is revenue +207.9%, EPS -616.7%, free cash flow +89.5% with operating margin -1761.2% and ROIC 66.3%. Valuation already assumes a fairly strong business story at price/sales 51.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TBRIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+207.9% vs +7.6% peer median
Operating Margin
Below sector median
-1761.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Dec 30, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +207.9% and EPS is at -616.7%, with operating margin around -1761.2%.
The next real check-in already has a date
The next earnings event is scheduled for Jun 25, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged -1.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Dec 30, 2025 | โ | -5.0% | +7.5% | +17.5% |
2023 Oct 31, 2023 | โ | -10.0% | -10.0% | -41.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TBRIF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TBRIF Max Drawdown
-67.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TBRIF and SPY.
Company Overview
Therma Bright Inc.
Other OTC
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
- Leadership
- Roberto Fia
- IPO Date
- Jan 8, 2021
- Street Address
- 1173 Dundas Street East
- Mailing
- Toronto, ON, M4M 3P1
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- 844 274 6837
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 51.6
- Price/Book
- โ
Growth
- Revenue
- +207.9%
- EPS
- -616.7%
- Free Cash Flow
- +89.5%
Profitability
- Gross Margin
- 22.1%
- Operating Margin
- -1761.2%
- Net Margin
- -5884.3%
- ROE
- 420.7%
- ROIC
- 66.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.10
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.